Octagon Capital Advisors LP 4 D Molecular Therapeutics, Inc. Transaction History

Octagon Capital Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$6.85 - $25.46 $909,330 - $3.38 Million	-132,749 Reduced 20.98%	499,996 $11.1 Million
Q2 2022 Aug 15, 2022	SELL	$5.68 - $15.99 $5.31 Million - $14.9 Million	-934,150 Reduced 59.62%	632,745 $4.42 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $208,257 - $358,278	15,825 Added 1.02%	1,566,895 $23.7 Million
Q4 2021 Feb 14, 2022	BUY	$19.56 - $32.94 $14.1 Million - $23.7 Million	719,803 Added 86.59%	1,551,070 $34 Million
Q2 2021 Aug 16, 2021	BUY	$22.2 - $42.29 $10.1 Million - $19.2 Million	452,979 Added 119.74%	831,267 $20 Million

Q1 2021 May 17, 2021	BUY	$35.94 - $52.67 $18,365 - $26,914	511 Added 0.14%	378,288 $16.4 Million
Q4 2020 Feb 16, 2021	BUY	$38.43 - $47.36 $14.5 Million - $17.9 Million	377,777 New	377,777 $15.7 Million

157

50.3M

718K

370K

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $675M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.